194 related articles for article (PubMed ID: 35724850)
1. Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation.
Chaekal OK; Gomez-Arteaga A; Chen Z; Soave R; Shore T; Mayer S; Phillips A; Hsu JM; Drelick A; Kodiyanplakkal RPL; Plate M; Satlin MJ; van Besien K
Transplant Cell Ther; 2022 Sep; 28(9):618.e1-618.e10. PubMed ID: 35724850
[TBL] [Abstract][Full Text] [Related]
2. [COVID-19 vaccination for allogeneic hematopoietic stem cell recipients].
Nagafuji K
Rinsho Ketsueki; 2022; 63(9):1067-1077. PubMed ID: 36198531
[TBL] [Abstract][Full Text] [Related]
3. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
Bashey A; Solomon SR
Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530
[TBL] [Abstract][Full Text] [Related]
4. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
[TBL] [Abstract][Full Text] [Related]
5. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
Canti L; Humblet-Baron S; Desombere I; Neumann J; Pannus P; Heyndrickx L; Henry A; Servais S; Willems E; Ehx G; Goriely S; Seidel L; Michiels J; Willems B; Liston A; Ariën KK; Beguin Y; Goossens ME; Marchant A; Baron F
J Hematol Oncol; 2021 Oct; 14(1):174. PubMed ID: 34689821
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E
Front Immunol; 2023; 14():1174289. PubMed ID: 37207199
[TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
[TBL] [Abstract][Full Text] [Related]
8. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
Front Immunol; 2022; 13():907615. PubMed ID: 35812459
[TBL] [Abstract][Full Text] [Related]
9. Robust spike-specific CD4
Federico L; Tvedt THA; Gainullin M; Osen JR; Chaban V; Lund KP; Tietze L; Tran TT; Lund-Johansen F; Kared H; Lind A; Vaage JT; Stratford R; Tennøe S; Malone B; Clancy T; Myhre AEL; Gedde-Dahl T; Munthe LA
Front Immunol; 2023; 14():1210899. PubMed ID: 37503339
[TBL] [Abstract][Full Text] [Related]
10. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Ali H; Ngo D; Aribi A; Arslan S; Dadwal S; Marcucci G; Nakamura R; Forman SJ; Chen J; Al Malki MM
Transplant Cell Ther; 2021 Nov; 27(11):938.e1-938.e6. PubMed ID: 34274492
[TBL] [Abstract][Full Text] [Related]
13. Development of donor specific antibodies after SARS-CoV-2 vaccination in kidney and heart transplant recipients.
McCune TR; Bray RA; Baran DA; Toepp AJ; Forte SJ; Gilgannon LT; Williams T; Chen S; Sadr H; Gebel HM; Herre JM
Transpl Immunol; 2022 Dec; 75():101722. PubMed ID: 36152939
[TBL] [Abstract][Full Text] [Related]
14. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
15. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M
Front Immunol; 2023; 14():1169666. PubMed ID: 37153556
[TBL] [Abstract][Full Text] [Related]
16. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
[TBL] [Abstract][Full Text] [Related]
17. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
18. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.
Einarsdottir S; Martner A; Waldenström J; Nicklasson M; Ringlander J; Arabpour M; Törnell A; Wiktorin HG; Nilsson S; Bittar R; Nilsson M; Lisak M; Veje M; Friman V; Al-Dury S; Bergström T; Ljungman P; Brune M; Hellstrand K; Lagging M
Blood Adv; 2022 May; 6(9):2723-2730. PubMed ID: 35286374
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
EClinicalMedicine; 2023 May; 59():101983. PubMed ID: 37128256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
